April 2, 2020
Pharmetheus closely monitors the developing COVID-19 pandemic. We are continuing to run our operations largely as normal with close to full capacity. For some time now we have taken measures to ensure the safety and health of our employees and collaborators. These measures have included restrictive travel policies, enabling remote working and the provision of regular updates on our measures taken as a result of the dynamic and emerging situation.
We remain fully committed to deliver and satisfy the needs of our clients – thank you for your continued partnership.
June 26, 2020
The majority of the Pharmetheus staff will continue working from home during the summer period. A new decision on continued travel restrictions will be taken in September.
Thank you for your collaboration!
September 2, 2020
We continue to monitor the development of the COVID-19 Pandemic, while enabling our employees to continue working remotely. Pharmetheus travel policies are still restrictive. We are looking forward to a productive autumn, working mostly from our home offices!
Peter Milligan, CEO
Marie Sandström, COO
On behalf of the Pharmetheus Team
Pharmetheus is part of COVID 19 Pharmacology Resource center, which purpose is to conquer COVID-19 with clinical pharmacology, innovation, and collaboration. Read more about COVID 19 Pharmacology Resource center.
Pharmetheus is currently working with a number of clients to address the impact of the current COVID-19 epidemic to their ongoing clinical drug development programs. We see the current situation as both a challenge to our industry/sector but also an opportunity for appropriate and quantitative approaches to mitigate upon these challenges. We believe there are “fit for purpose” options for a broad range of plausible scenarios in clinical trial conduct that have emerged or could emerge. See our approach.
Pharmetheus working remotely – at one of our team meetings.